M1FG
NTLA icon

Mach-1 Financial Group’s Intellia Therapeutics NTLA Stock Holding History

Mach-1 Financial Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-34,813
Closed -$327K – 359
2025
Q2 		$327K Buy
+34,813
New +$286K 0.1% 185

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mach-1 Financial Group's NTLA Position: Q3 2025 in Review

Mach-1 Financial Group sold out of Intellia Therapeutics (NTLA) in Q3 2025, closing a stake of 34,813 shares — an estimated $327K sold.

Mach-1 Financial Group first reported a position in NTLA in Q2 2025 and held it in 1 quarter. The position peaked at $327K in Q2 2025. 282 funds tracked by Wall St. Rank hold NTLA as of Q3 2025.

  • Mach-1 Financial Group reported no remaining Intellia Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Mach-1 Financial Group sold 34,813 Intellia Therapeutics shares in Q3 2025, an estimated $327K.
  • Mach-1 Financial Group first reported a position in Intellia Therapeutics in Q2 2025 and held it in 1 quarter.
  • Mach-1 Financial Group's Intellia Therapeutics position peaked at $327K in Q2 2025.
  • 282 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2025.

Based on Mach-1 Financial Group's 13F filing for Q3 2025, filed 12 Nov 2025.